Article
Genetic variants in cellular transport do not affect mesalamine response in ulcerative colitis.
PloS one - 1 Jan 2018
Moran Christopher J, Huang Hailiang, Rivas Manuel, Kaplan Jess L, Daly Mark J, Winter Harland S
Abstract excerpt
BACKGROUND AND AIMS: Mesalamine is commonly used to treat ulcerative colitis (UC). Although mesalamine acts topically, in vitro data suggest that intracellular transport is required for its beneficial effect. Genetic variants in mucosal transport proteins may affect this uptake, but the clinical relevance of these variants has not been studied. The aim of this study was to determine whether variants in genes...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
